In Vivo Therapeutics Core
In Vivo Therapeutics Core
批准号:
9793158
负责人:
Karen Elizabeth Pollok
金额:
$10.28万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
AdultAnimal ModelAnimalsAutopsyBreedingCancer CenterCancer Center Support GrantCatchment AreaCommon CoreConsultationsCore FacilityData AnalysesDevelopmentDoseDrug KineticsEducationEquipmentEventExperimental DesignsFinancial SupportFutureGenderGenerationsHematopoietic Stem Cell TransplantationHuman ResourcesHypoxiaImageIn VitroIndianaIndividualInfrastructureInvestigationLiquid substanceMalignant NeoplasmsMethodologyMonitorMouse StrainsMusNCI Center for Cancer ResearchPatientsPeer ReviewPharmacodynamicsPharmacologyProceduresProductivityRadiationResearchResearch ActivityResearch PersonnelResource SharingResourcesRouteSamplingScientistServicesSiteSolid NeoplasmStructureStudentsSurveysTechnologyTestingTherapeuticTimeToxicity TestsTrainingUniversitiesUniversity resourcesValidationVendorWorkXenograft ModelXenograft procedureanimal facilityanticancer researchbasecancer biomarkerscancer therapycost effectivecost effectivenesseducation resourcesefficacy testingexperimental studyimaging systemimprovedin vivoinnovationinvestigator-initiated trialirradiationlive cell imagingmembermouse modelnew therapeutic targetnext generationnovelnovel therapeuticspediatric patientspre-clinicalpreclinical toxicitystudent training
中文摘要
摘要:体内治疗学核心(IVTC)
英文摘要
ABSTRACT, In Vivo Therapeutics Core (IVTC)
The In Vivo Therapeutics Core (IVTC) is a multi-faceted shared resource facility of the Indiana University Melvin
and Bren Simon Cancer Center (IUSCC) that was established to facilitate the discovery and testing of novel
pharmacological & cellular therapies. The IVTC is divided into five hubs of research expertise: state-of-the-art
equipment for cancer research, breeding of specialized mouse strains, preclinical toxicity and efficacy testing in
xenograft models, patient-derived xenografts, and hematopoietic stem-cell transplant studies. Importantly, the
IVTC is structured in a way to provide the necessary infrastructure, oversight, and expertise required to
successfully meet the needs of the IUSCC investigators. Given the heavy reliance of IUSCC investigators on
services provided by IVTC, there is strong rationale to support this centralized shared resource that will facilitate
the discovery of new therapies for cancers prominent in the catchment area of Indiana. In the past year, 67% of
IVTC users were peer-reviewed Cancer Center members and accounted for 94% of the services invoiced. For
the majority of IUSCC members, utilization of mouse models is an essential component of their ongoing research
activities focused on development of novel therapies for liquid and solid tumors. To support the needs of the
membership, the Aims of the IVTC are: (1) to maintain on-site breeding colonies of mice and establish
patient-derived xenografts essential for the exploration, testing, and refinement of novel cancer
therapeutics; (2) to provide specialized core services and technology applicable to in vivo studies; and
(3) to serve as a consultation and educational resource for IUSCC investigators and trainees. Specifically,
the IVTC manages the Radiation facility and will perform irradiation services needed for in vitro and in vivo
experiments, including hematopoietic stem-cell transplantations. The IVTC will coordinate all aspects of
procedures and provide assistance with experimental design, regulatory requirements, methodology, and data
interpretation for each research hub. Shared equipment maintained by the IVTC provides investigators with
access to a recently acquired IncuCyteZOOM Live-Cell Imaging System and a hypoxia workstation which are
both available for direct use or in partnership with technical staff in the IVTC. In addition, the IVTC will work with
IUSCC research teams to coordinate timely delivery of mice and samples to other Core facilities within the IUSCC
and the IUSM. As a centralized facility, the IVTC will provide IUSCC investigators advanced resources for
analytical and investigational studies essential for the preclinical validation of novel drug targets and biomarkers
of cancer so that innovative investigator-initiated trials can be successfully developed.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Experimental Mouse Resources Core
-
批准号:10681258
-
项目类别:
-
资助金额:$22.74万
-
财政年份:2015
-
负责人:Karen Elizabeth Pollok
-
依托单位:
Enrichment Program
-
批准号:10681266
-
项目类别:
-
资助金额:$10.48万
-
财政年份:2015
-
负责人:Karen Elizabeth Pollok
-
依托单位:
Enrichment Program
-
批准号:10206542
-
项目类别:
-
资助金额:$15.44万
-
财政年份:2015
-
负责人:Karen Elizabeth Pollok
-
依托单位:
Experimental Mouse Resources Core
-
批准号:10473856
-
项目类别:
-
资助金额:$21.76万
-
财政年份:2015
-
负责人:Karen Elizabeth Pollok
-
依托单位:
Experimental Mouse Resources Core
-
批准号:10206539
-
项目类别:
-
资助金额:$15.44万
-
财政年份:2015
-
负责人:Karen Elizabeth Pollok
-
依托单位:
Enrichment Program
-
批准号:10473865
-
项目类别:
-
资助金额:$10.02万
-
财政年份:2015
-
负责人:Karen Elizabeth Pollok
-
依托单位:
Dual Targeting of DNA Repair and p53 pathways for treatment of brain cancer
-
批准号:7986836
-
项目类别:
-
资助金额:$32.19万
-
财政年份:2010
-
负责人:Karen Elizabeth Pollok
-
依托单位:
Dual Targeting of DNA Repair and p53 pathways for treatment of brain cancer
-
批准号:8110715
-
项目类别:
-
资助金额:$31.23万
-
财政年份:2010
-
负责人:Karen Elizabeth Pollok
-
依托单位:
Dual Targeting of DNA Repair and p53 pathways for treatment of brain cancer
-
批准号:8473057
-
项目类别:
-
资助金额:$29.06万
-
财政年份:2010
-
负责人:Karen Elizabeth Pollok
-
依托单位:
Dual Targeting of DNA Repair and p53 pathways for treatment of brain cancer
-
批准号:8676458
-
项目类别:
-
资助金额:$29.88万
-
财政年份:2010
-
负责人:Karen Elizabeth Pollok
-
依托单位:
In Vivo Therapeutics Core
-
批准号:10247608
-
项目类别:
-
资助金额:$10.28万
-
财政年份:1999
-
负责人:Karen Elizabeth Pollok
-
依托单位:
In Vivo Therapeutics Core
-
批准号:10477071
-
项目类别:
-
资助金额:$10.28万
-
财政年份:1999
-
负责人:Karen Elizabeth Pollok
-
依托单位:
FUNCTIONAL ANALYSIS OF T-CELL ANTIGEN 4-1BB
-
批准号:2058727
-
项目类别:
-
资助金额:$1.43万
-
财政年份:1994
-
负责人:Karen Elizabeth Pollok
-
依托单位:
海外基金